DNA ploidy analysis of borderline epithelial ovarian tumours by Lodhi, Saba et al.
eCommons@AKU
Department of Pathology and Laboratory Medicine Medical College, Pakistan
October 2000
DNA ploidy analysis of borderline epithelial
ovarian tumours
Saba Lodhi
Aga Khan University
Sabeen Najam
Aga Khan University
Shahid Pervez
Aga Khan University, shahid.pervez@aku.edu
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Obstetrics and Gynecology Commons, Pathology Commons, and the Women's
Health Commons
Recommended Citation
Lodhi, S., Najam, S., Pervez, S. (2000). DNA ploidy analysis of borderline epithelial ovarian tumours. Journal of Pakistan Medical
Association, 50(10), 349-351.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/289
DNA Ploidy Analysis of Borderline Epithelial Ovarian Tumors
Saba Lodhi,Sabeen Najam,Shahid Pervez ( Department of Pathology, The Aga Khan University Hospital, Karachi. ) 
Abstract 
Objective: Borderline epithelial ovarian tumors not uncommonly pose a great difficulty to surgical
pathologists as morphologically they may show very similar features as those of malignant epithelial
tumors except invasion. However it is important to separate these from their invasive counterparts
because of their superior prognosis. Recently, attention has been focussed on the prognostic value of
flow cytometric analysis of DNA ploidy in borderline epithelial ovarian tumors. The purpose of this
study is to investigate whether flow cytometric analysis of cellular DNA content acts as a useful
adjunct to the histopathological diagnosis of borderline malignancy.
Materials and Methods: Fifteen histologically confirmed borderline serous epithelial tumors of the
ovary were selected. Samples were analyzed on a FACScan flow cytometer using the software
MODFIT. A total of 10,000 nuclei were counted each time.
Results: The mean CV for the 15 cases was 3.67 (Range 2.4-5.0). In the DNA histograms a diploid
sample was defined as one that had a single Go/Cl peak. An aneuploid tumour was defined as one that
displayed an additional distinct peak. All 15 cases of borderline serous epithelial tumors showed a
diploid stemlinc with DNA index between 0.9-i .10
Conclusion: This study suggests that aneuploidy if ever demonstrated in histological confirmed
borderline tumors should prompt extensive sampling of the tumor and a close follow up (JPMA 50:
349, 2000).
Introduction 
Borderline ovarian tumors or turnouts of low malignant potential (LMP) comprise approximately
7.5%¬15% of all epithelial ovarian neoplasms, most of which have serous or mucinous Features1. It is
important to separate these from the invasive tumors because of their superior prognosis2. This
distinction however, is not always easy, particularly in non-serous types and there is some controversy
regarding the arbitrary diagnostic criteria used to designate the borderline tumors3. The presence of
stromal invasion is an important histologic criterion for separating ovarian carcinomas from borderline
lesions, however tangential sectioning of surface lesions may lead to erroneous results. The focus of
present day cancer research to some extent has shifted from the exclusive subjective and semi-
quantitative diagnostic and prognostic parameters (stage and grade) to quantitative measurements of
fundamental tumor properties directly related to their growth and metastatic potential, like DNA
content and ploidy. The development of flow cytometry has introduced a new possibility for routine
DNA measurements with high speed and high resolution. Prognostic information of flow cytometric
DNA measurements of malignant ovarian tumor samples has been reported4,5 and aneuploidy
recognized as a significant adverse prognostic indicator of ovarian carcinoma6. However data on
borderline ovarian tumors is scarce. Where most studies identify flow cytometric analysis of cellular
DNA content as a useful adjunct to the histopathological diagnosis of borderline malignancy, others
have cast doubts on its role in predicting which tumor(s) will behave in a more aggressive fashion7,14.
The purpose of this study is to further explore whether tumor cell DNA content in borderline ovarian
tumors may be used as an adjunct to support the histologic diagnosis.
Materials and Methods 
Selection of cases for ploidy analysis
Formalin fixed, paraffin embedded tissue blocks were selected from the pathology record of the Aga
Khan University Hospital. Fifteen cases of histologicaly confirmed borderline ovarian tumors were
selected. Only those blocks were selected which on screening showed a good proportion of
representative tissue.
Sample preparation
Three to five 25 urn thick sections were obtained/cut from routinely fixed, paraffin embedded tissue
blocks for each case. Sections were dewaxed in two changes (2 x 10 minutes) of xylene and rehydrated
in 100, 90, 70 and 50% alcohol for 10 minutes each. The sections were then rinsed in PBS x 10 minutes
and incubated in 0.5% pepsin solution at pH 1.5 and 37° C for 30 minutes. Hypodermic needles of 40
and 25 bore were used to break up the tissue. Released nuclei were spun, washed and cytopreps made
to check their condition staining was done with propidium iodide (P1) in isoton (250 ug/ml) containing
I mg/mI RNAase for 30 minutes at 4°C before analyzing on FACScan machine.
Flow Cytometry
Samples were analyzed on a FACScan flow cytometer using the software MODFIT, Flow cytometric
data was acquired and displayed in standard two parameter dot plots using FL2 width and FL2 area as
the axes. This allowed to draw gates in which debris below the first Go/C I distribution and particles
with extended time in flight (presumed doublets) were excluded from analysis using carefully defined
and standardized gating criteria. FL2 area signals were then used to generate single parameter DNA
histograms. Specimens were rejected if the median half-peak coefficient of variation (CV) of the
diploid peak was more than 5. A total of 10,000 nuclei were counted in each case.
Results 
Tumour staging and typing
Of the fifteen patients with a histological diagnosis of borderline ovarian epithelial malignancy,
majority had FIGO Stage I, typed mostly as serous.
Histogram interpretation
The mean coefficient of variation (CV) for the IS cases was 3.67(range 2.4-5). In the DNA histograms
a diploid sample was defined as one that had a single Go/GI peak (Figure Ia).
An aneuploid tumour was defined as one that displayed an additional distinct peak (Figure I b).
The DNA index was calculated as the ratio of the mean channels of the aneuploid Go/G I peak to the
diploid Go/C I peak.
All 15 cases of borderline serous ovarian tumors showed a diploid stemline with DNA index between
0.9-.10. None of the cases demonstrated aneuploidy despite multiple sampling (3-5 of each  case).
Discussion 
Common epithelial ovarian tumors are subgrouped into benign, borderline and invasive malignant
categories under recommendations of FIGO and WHO14. The usual finding of an indolent clinical
course and generally improved prognosis in patients support the value of this categorization with
borderline tumors compared to their invasive counterparts15. However the identification of borderline
tumors are subject to considerable interobserver variability 16 and the validity of their arbitrary
categorization can be challenged on a number of grounds17.
The flow cytometric analysis of cellular DNA content is relatively simple to perform and is highly
reproducible. The most extensive work on its clinical usefulness in gynecological pathology has been
in association with prognosis of epithelial carcinomas of the ovary and in the differential diagnosis and
prognosis of possible molar gestations. Much less data is available on the DNA content of borderline
tumour and its biological significance. However a large number of studies have demonstrated
prognostic significance of flow cytometric analyses of cellular DNA content in general. Kuhn et  al6
observed that borderline tumors in 7 of 8 women were diploid and all but one of the women was alive
after a mean follow up period of 48 months. Likewise Friedlander et al7 studied ploidy status in 44
women with borderline tumors and reported that 42 were diploid. Of the 2 women with aneuploid
tumors one died 7 months after diagnosis. All 42 women with diploid DNA status were alive after an
average of 3 years of follow up. As part of a larger follow up study of borderline ovarian tumors
survival Kaern et. al10, Determined ploidy status in a nested case control study of 64 women with
mucinous and borderline ovarian tumors. Of the 30 women who died and 4 women with disease
recurrence after 7 years of follow tip (odds ratio 1.l, pc 0.0l). Aneuploidy was also more strongly
associated with poor survival in women with mucinous tumors. It has been shown in a very large series
from the Norwegian Radium Hospital in Oslo, with long term follow up. that DNA aneuploidy of
serous (P160 stage> I) and mucinous borderline tumors is clearly associated with poor prognosis18,19.
There are several other small series that have confirmed the value of DNA cytomeiry in this respect.
Some recent studies have however cast doubts. liarlow et. al20 reported a case control study negating
any significant association between ploidy and prognosis of borderline ovarian tumors. Data from
women who had died of borderline ovarian tumors were compared to an age, histology and histologic
stage matched sample of women with the same diagnosis still living after atleast five years of follow
up. 25% of the women who died and 24% of those still alive had aneuploid DNA tumors.
Seidman et. al.12 reported a similar finding. They analyzed 40 serous tumors of low malignant potential
(STLMP) and compared with 26 serous carcinomas, The mean follow up periods were 14.3 years for
stage I STLMP and 8.3 years for stage III STLMP 40% of STLMP as compared to 54% of serous
carcinomas were aneuploid. 50% of the STLMPs, which progressed. had aneuploidy, as did 38% of
those that did not. Correlation between diploidy and superior prognosis was rejected on the basis that 3
of 4 DNA diploid tumors progressed and 3 of 6 that did not progress were aneuploid. False diploid and
aneuploid sample samples may offer an explanation here. The samples used in both the studies were
de-parallelized. When analyzing de-paraffinized material it is imperative to examine the microscopic
slides to assure that a substantial amount of normal tissue is present to provide the normal internal
diploid control. Samples containing necrosis may similarly result in false aneuploid peaks21.
The nature of the tissue analyzed may also affect the accuracy of the DNA analysis. It has been shown
that considerable hcterogeaeity in DNA content is present in most neoplasms. It is thus recommended
that multiple samples (generally 3 or more) from a neoplasm be examined. Seidman et. al. had a few
eases ia their study with one sample only. which could have resulted in the erroneous results.
The subjectivity of the interpretation of the DNA histograms22 and the absence of standardized criteria
for histogram diagnosis most probably account in part for the variations in DNA ploidy results for the
same types of tumors that are reported in literature.
In the light of our results and the already existing data, we conclude that aneuploidy if ever
demonstrated in histologically borderline tumors should prompt extensive sampling of the tumor and a
close follow up. We thus believe that flow eytometric analysis of cellular DNA content may
complement conventional histopathological diagnosis by providing an objective parameter that
correlates with the biological behavior and may identify the few genuine aggressive borderline ovarian
epithelial neoplasms that show clinical progression.
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